Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparative Study on the Efficacy of First-generation Versus Third-generation EGFR TKIs as First-line Therapy for Advanced NSCLC With EGFR Exon 19 Deletion-insertion (19delins) Mutation

NCT07458919 is registered in ClinicalTrials.gov with Fuzhou General Hospital as lead sponsor.

NCT NCT07458919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07458919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparative Study on the Efficacy of First-generation Versus Third-generation EGFR TKIs as First-line Therapy for Advanced NSCLC With EGFR Exon 19 Deletion-insertion (19delins) Mutation
Lead sponsor
Fuzhou General Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 30, 2026
Completion date
October 30, 2030
Enrollment
94 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer